Actively Recruiting
Study of Duobrii with Biologic Therapy for Adults with Moderate Psoriasis
Led by Psoriasis Treatment Center of Central New Jersey · Updated on 2020-04-30
25
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of DUOBRII in combination with biologic therapy in adults with psoriasis affecting 2% to 10% of their body surface area. This open-label pilot study involves 25 participants who have been receiving biologic treatments for at least 24 weeks. The study aims to assess how DUOBRII impacts psoriasis when added to ongoing biologic therapy. Participants will apply DUOBRII daily for the first 4 weeks, followed by every other day for the next 4 weeks, over a total treatment period of 12 weeks. This study does not include a placebo group and is conducted at a single center. The focus is on observing changes in the extent of psoriasis during and after the treatment period. During the study, participants will be monitored for improvements in their psoriasis, specifically measuring the percentage of body surface area affected at 8 weeks. Researchers will collect data on skin condition and treatment adherence. The study includes assessments at baseline and follow-up visits throughout the treatment period to evaluate safety and efficacy.
CONDITIONS
Brief Title
Duobrii in Combination With Biologics
Research Team
J
Jerry Bagel, MD
E
Elise Nelson
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
